Business Description
Eyenovia Inc
NAICS : 325412
SIC : 2834
ISIN : US30234E1047
Description
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.92 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 1.79 | |||||
| Debt-to-EBITDA | -0.67 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -8.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 14.3 | |||||
| 3-Year EPS without NRI Growth Rate | 11.1 | |||||
| 3-Year FCF Growth Rate | -29 | |||||
| 3-Year Book Growth Rate | -31.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.64 | |||||
| 9-Day RSI | 43.9 | |||||
| 14-Day RSI | 37.78 | |||||
| 6-1 Month Momentum % | -9.82 | |||||
| 12-1 Month Momentum % | -78.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | |||||
| Quick Ratio | 2.16 | |||||
| Cash Ratio | 1.56 | |||||
| Days Inventory | 7300 | |||||
| Days Payable | 133626.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.2 | |||||
| Shareholder Yield % | -78.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -635175 | |||||
| Net Margin % | -681525 | |||||
| FCF Margin % | -695175 | |||||
| ROE % | -199.42 | |||||
| ROA % | -88.89 | |||||
| ROIC % | -234.4 | |||||
| ROC (Joel Greenblatt) % | -377.03 | |||||
| ROCE % | -100.54 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.54 | |||||
| Price-to-Tangible-Book | 4.71 | |||||
| EV-to-EBIT | -1.28 | |||||
| EV-to-Forward-EBIT | -1.01 | |||||
| EV-to-EBITDA | -1.33 | |||||
| EV-to-Revenue | 7985.75 | |||||
| EV-to-Forward-Revenue | 5.37 | |||||
| EV-to-FCF | -1.11 | |||||
| Price-to-Net-Current-Asset-Value | 35.35 | |||||
| Earnings Yield (Greenblatt) % | -78.13 | |||||
| FCF Yield % | -83.01 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers